Comparison · NCT00705679-b5e3e0dc
TFV Gel vs Placebo Gel: Number of HIV-1 Infections of Tenofovir 1% Gel and Vaginal Placebo Gel Arms
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. TFV Gel vs Placebo Gel: Number of HIV-1 Infections of Tenofovir 1% Gel and Vaginal Placebo Gel Arms. Trial comparisons, record NCT00705679-b5e3e0dc. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT00705679-b5e3e0dc
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.0612 | 0.048 | 0.0779 | wilson | |
| Risk in group 2 | 0.0703 | 0.056 | 0.0879 | wilson | |
| Risk difference, group 1 minus group 2 | -0.00904 | -0.0311 | 0.0129 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.871 | 0.625 | 1.21 | log | |
| Odds ratio, group 1 over group 2 | 0.863 | 0.605 | 1.23 | log | |
| Number needed to treat, for one fewer participant with the outcome on TFV Gel than on Placebo Gel | 111 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Group 2 names the comparator: placebo.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | TFV Gel | Application of tenofovir 1% vaginal gel once daily Tenofovir 1% vaginal gel: 1 gm/100 ml of 1% gel | 61 | 996 | OG000 |
| Group 2 | Placebo Gel | Application of placebo gel once daily Tenofovir placebo gel: placebo gel | 70 | 996 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- PRIMARY
- Title
- Number of HIV-1 Infections of Tenofovir 1% Gel and Vaginal Placebo Gel Arms
- Description
Participants were followed for up to 30 months. Participants were tested monthly for HIV-1 and positive rapid test results were confirmed by means of an enzyme-linked immunosorbent assay (EIA) and subsequent Western blotting (WB).
- Time frame
- For up to 30 months of follow-up
- Population
All participants randomized except for those with no follow-up HIV testing or those determined to be HIV-positive at the time of randomization by PCR testing of plasma samples stored at the enrollment visit.
Source ClinicalTrials.gov
Trial
- Title
- Safety and Effectiveness of TFV 1% Gel, TDF Tablets, and FTC/TDF Tablets in Preventing HIV in Women
- NCT number
- NCT00705679
- Phases
- PHASE2
- Conditions
- HIV Infections
- Interventions
Emtricitabine/tenofovir disoproxil fumarate, Emtricitabine/tenofovir disoproxil fumarate placebo, Tenofovir disoproxil fumarate, Tenofovir disoproxil fumarate placebo, Tenofovir 1% vaginal gel, Tenofovir placebo
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- Results first posted
- 2016-02-10
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT00705679?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT00705679-b5e3e0dc